A Phase 2 interventional study of ONO-1110 and Placebo in Social Anxiety Disorder (SAD), sponsored by Ono Pharmaceutical Co., Ltd.. Completed at 27 sites in Japan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Social Anxiety Disorder
368 studies on the registry are indexed under Phobia, Social; 59 are open to participants now.
This study's enrollment of 115 is above the median of 76 across 339 interventional studies indexed under Phobia, Social.
Browse Phobia, Social studies →Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with a current or past history of psychiatric or neurological disorders that meet any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ONO-1110 · Drug: Placebo
Drug: ONO-1110 · Drug: Placebo
ONO-1110 tablets once a day
Placebo tablets once daily
Change in L-SAS J(Liebowitz Social Anxiety Scale Japanese version) total score from baseline to Week 12 of the treatment period
Time frame: Up to 19 weeks
The transition of LSAS-J(Liebowitz Social Anxiety Scale Japanese version) total score from baseline to Week 8 of the treatment period
Time frame: Up to 19 weeks
The transition of LSAS-J(Liebowitz Social Anxiety Scale Japanese version) Fear or Anxiety score from baseline to Week 8 of the treatment period
Time frame: Up to 19 weeks
The transition of LSAS-J(Liebowitz Social Anxiety Scale Japanese version) Avoidance score from baseline to Week 8 of the treatment period
Time frame: Up to 19 weeks
Responder rates of LSAS-J(Liebowitz Social Anxiety Scale Japanese version) total score at 1, 2, 4, 6, 8,10and 2 weeks of the treatment period
Responder is defined as a reduction of 30% or more in LSAS-J(Liebowitz Social Anxiety Scale Japanese version)total score from baseline
Time frame: Up to 19 weeks
Remitted patient rates of LSAS-J(Liebowitz Social Anxiety Scale Japanese version) total score at 1, 2, 4, 6, 8, 10 and 12 weeks of the treatment period
Remitted patient is defined as a LSAS-J(Liebowitz Social Anxiety Scale Japanese version) total score of 30 or less.
Time frame: Up to 19 weeks
Transition of CGI-S(Clinical Global Impression of illness Severity) score from baseline to Week 12 of the treatment period
Time frame: Up to 19 weeks
Transition of SDISS(Sheehan Disability Scale) score from baseline to Week 12 of the treatment period
Time frame: Up to 19 weeks
Plasma ONO-1110 concentrations
Time frame: Up to 19 weeks
Adverse Events
Time frame: Up to 19 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in May 2026, 15 months.
Of 15 phase 2 interventional studies under Phobia, Social, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 15 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ONO-1110
Ono Pharmaceutical Co., Ltd. →